1-环己基-3-(4-羟基苯基)脲 | 38652-23-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-环己基-3-(4-羟基苯基)脲
• 英文名称: 1-cyclohexyl-3-(4-hydroxyphenyl)urea
• CAS: 38652-23-2
• 化学式: C₁₃H₁₈N₂O₂
• 分子量: 234.298
• InChiKey: RQLAWYIMRBTCHU-UHFFFAOYSA-N

物化性质

• 熔点：
  >200°C (dec.)
• 溶解度：
  可溶于二甲基亚砜、甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  61.4
• 氢给体数：
  3
• 氢受体数：
  2

安全信息

• 海关编码：
  2924299090
• 储存条件：
  室温密封，干燥保存。

反应信息

• 作为反应物：
  描述：

  1-环己基-3-(4-羟基苯基)脲 在 mushroom tyrosinase E_.C_. 1.14.18.1 、 氧气 作用下， 以 phosphate buffer 、 乙腈 为溶剂， 以80%的产率得到环己胺
  参考文献：
  名称：

  酪氨酸酶不稳定的胺保护基的开发。

  摘要：

  [反应：见正文]描述了两个新颖的胺保护基的开发。因此，已经将多种胺转化为脲，并且已经证明了它们在暴露于蘑菇酪氨酸酶时会脱保护（EC 1.14.18.1）。

  DOI：

  10.1021/ol040042i
• 作为产物：
  描述：

  4-氨基苯硼酸频哪醇酯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 5.17h， 生成 1-环己基-3-(4-羟基苯基)脲
  参考文献：
  名称：

  新型吡啶并[2,3-d]嘧啶脲衍生物的合成及抗肿瘤活性

  摘要：

  一系列新型N- (3-((6-溴吡啶并[2,3- d ]嘧啶-4-基)氧基)苯基)吡咯烷-1-甲酰胺和1-(3-((6-溴吡啶并[2, 3- d合成]嘧啶-4-基）氧基）苯基）-3-丙基脲衍生物。使用索拉非尼作为阳性对照药物，评估了它们在体外对人乳腺癌细胞 (MCF-7) 和人结肠癌细胞 (HCT-116) 的抗肿瘤活性。抗癌生物测定表明，几种化合物对 MCF-7 和 HCT-116 细胞表现出明显的抗癌活性。特别是化合物9g和8b对 HCT-116 和 MCF-7 细胞的抑制作用最为显着，抑制率分别为 25.56% 和 26.46%。此外，合成的含有脲基部分的吡啶[2,3- d ]嘧啶衍生物在体外对MCF-7和HCT-116细胞具有抗肿瘤活性。

  DOI：

  10.1002/jhet.4287

文献信息

• Synthesis and evaluation of uterine relaxant activity for a novel series of substituted p-hydroxyphenylethanolamines
  作者：C.L. Viswanathan、A.S. Chaudhari

  DOI：10.1016/j.bmc.2006.06.006

  日期：2006.10

  Novel racemic 1-(4-hydroxyphenyl)-2-[3-(substituted phenoxy)-2-hydroxy-1-propyl]aminopropan-1-ol hydrochlorides (9a-h) were synthesized by condensing racemic 1-(p-hydroxyphenyl)-2-aminopropan-1-ol hydrochloride (6) with substituted aryloxymethyloxiranes (8a-h) in DMF in presence of anhydrous potassium carbonate and then reacting with dry hydrogen chloride gas. They were evaluated for uterine relaxant

  通过缩合外消旋1-（对羟基苯基）合成新型外消旋1-（4-羟基苯基）-2- [3-（取代苯氧基）-2-羟基-1-丙基]氨基丙烷-1-醇盐酸盐（9a-h）。 ）-2-氨基丙-1-醇盐酸盐（6）在无水碳酸钾存在下于DMF中与取代的芳氧基甲基环氧乙烷（8a-h）混合，然后与干燥的氯化氢气体反应。对离体大鼠子宫的体外子宫松弛活性和妊娠大鼠体内的子宫松弛活性进行了评估。使用大鼠子宫组织匀浆通过cAMP [3H]分析研究了它们的cAMP释放潜能，并评估了狗的心脏刺激潜能。所有化合物在体外均表现出有效的子宫松弛活性，并显着延迟了妊娠大鼠的分娩。除9b和9c外，它们的cAMP释放潜能均高于盐酸异苏比林。最后，与盐酸异苏必林相比，这些化合物的心脏刺激潜力微不足道。
• Design, synthesis, and biological evaluation of novel benzo[b]thiophene-diaryl urea derivatives as potential anticancer agents
  作者：Omid Zarei、Fereshteh Azimian、Maryam Hamzeh-Mivehroud、Javid Shahbazi Mojarrad、Salar Hemmati、Siavoush Dastmalchi

  DOI：10.1007/s00044-020-02559-8

  日期：2020.8

  A hybrid pharmacophore approach was applied to design and synthesize a series of benzo[b]thiophene-diaryl urea derivatives 17a–g with potential anticancer effect. In vitro antiproliferative activities of all target compounds were evaluated against HT-29 and A549 cancer cell lines. Three compounds 17b, 17d, and 17f exhibited antiproliferative activities on both cell lines comparable to that of the positive

  一种杂种药效团方法被用于设计和合成一系列具有潜在抗癌作用的苯并[b]噻吩-二芳基脲衍生物17a-g。评估了所有目标化合物对HT-29和A549癌细胞的体外抗增殖活性。三种化合物17b，17d和17f在两种细胞系中均显示出与阳性参考药物索拉非尼相当的抗增殖活性。值得注意的是，化合物17d的IC 50活性最高在HT-29和A549细胞上的分别值为5.91和14.64μM。基于DAPI染色和碘化丙啶（PI）染色，然后流式细胞仪分析，它还诱导HT-29细胞的G0 / G1期凋亡和细胞周期停滞。分子对接研究表明17d可以很好地结合VEGFR2受体的活性位点。总的来说，化合物17d可以被认为是有前途的支架，适合进一步优化开发新的抗癌剂。
• INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF INFLAMMATION
  申请人：Hammock D. Bruce

  公开号：US20070117782A1

  公开（公告）日：2007-05-24

  The invention provides compounds that inhibit epoxide hydrolase in therapeutic applications for treating hypertension. A preferred class of compounds for practicing the invention have the structure shown by Formula 1 wherein Z is oxygen or sulfur, W is carbon phosphorous or sulfur, X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R 1 -R 4 is hydrogen, R 2 is hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, R 4 is hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, R 1 and R 3 is each independently C 1 -C 20 substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, or heterocyclic.

  本发明提供了一些化合物，用于治疗高血压的治疗应用中，抑制环氧水解酶。实施本发明的优选化合物类别具有由式1所示的结构，其中Z为氧或硫，W为碳、磷或硫，X和Y各自独立地为氮、氧或硫，而X还可以是碳，R1-R4中至少有一个是氢，当X为氮时，R2为氢，但当X为硫或氧时，R2不存在，当Y为氮时，R4为氢，但当Y为硫或氧时，R4不存在，而R1和R3各自独立地为C1-C20取代或未取代的烷基、环烷基、芳基、酰基或杂环基。
• Design and synthesis of some new 6-bromo-2-(pyridin-3-yl)-4-substituted quinazolines as multi tyrosine kinase inhibitors
  作者：Ahmed K.B.A.W. Farouk、Heba Abdelrasheed Allam、Essam Rashwan、Riham F. George、Safinaz E-S. Abbas

  DOI：10.1016/j.bioorg.2022.106099

  日期：2022.11

  The present study involves design and synthesis of five series of 6-bromo-2-(pyridin-3-yl)-4-substituted quinazolines 9a-l, 11a-e, 13a-c, 14a-f and 15a-e. Candidates 9a-l and 11a-e were evaluated for their EGFR and HER2 inhibitory activity compared to Lapatinib. Compounds 9b, 9d, 9f, 11b and 11c were further screened for their in vitro cytotoxicity against two human breast cancer cell lines: AU-565

  本研究涉及设计和合成五个系列的 6-bromo-2-(pyridin-3-yl)-4-取代的喹唑啉9a-l、11a-e、13a-c、14a-f和15a-e。与拉帕替尼相比，评估了候选者9a-l和11a-e的 EGFR 和 HER2 抑制活性。除了正常乳腺细胞系MCF10A之外，化合物9b、9d、9f、11b和11c针对两种人乳腺癌细胞系：AU-565和MDA-MB-231进一步筛选了它们的体外细胞毒性。化合物9d显示相对于拉帕替尼(IC 50 = 0.48 µM)对 AU-565 细胞系 (IC 50  = 1.54 µM)具有显着的细胞毒性功效 ，而化合物9d和11c对 MDA-MB-231 显示出优异的细胞毒性 (IC 50  = 2.67和 1.75 µM）与拉帕替尼（IC 50  = 9.29 µM）相比。此外，与索拉非尼相比，测试了化合物13a-c、13a-c、14a-f和15a-e的
• Structural refinement of inhibitors of urea-based soluble epoxide hydrolases
  作者：Christophe Morisseau、Marvin H. Goodrow、John W. Newman、Craig E. Wheelock、Deanna L. Dowdy、Bruce D. Hammock

  DOI：10.1016/s0006-2952(02)00952-8

  日期：2002.5

  The soluble epoxide hydrolase (sEH) is involved in the metabolism of arachidonic, linoleic, and other fatty acid epoxides, endogenous chemical mediators that play an important role in blood pressure regulation and inflammation. 1,3-Disubstituted ureas, carbamates, and amides are new potent and stable inhibitors of sEH. However, the poor solubility of the lead compounds limits their use. Inhibitor structure-activity relationships were investigated to better define the structural requirements for inhibition and to identify points in the molecular topography that could accept polar groups without diminishing inhibition potency. Results indicate that lipophilicity is an important factor controlling inhibitor potency. Polar groups could be incorporated into one of the alkyl groups without loss of activity if they were placed at a sufficient distance from the urea function. The resulting compounds had a 2-fold higher water solubility. These findings will facilitate the rational design and optimization of sEH inhibitors with better physical properties. (C) 2002 Published by Elsevier Science Inc.